Expert Analysis

HIV Highlights From ICAAC

Source: CCO Independent Conference Coverage of the 2007 Interscience Conference on Antimicrobial Agents and Chemotherapy*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

HIV Highlights From ICAAC

Faculty:

Joseph J. Eron, Jr., MD
Joel E. Gallant, MD, MPH
Trevor Hawkins, MD

CME CREDIT INFORMATION

Release Date: 11/09/07

Expiration Date: 11/08/08

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.7 Nursing CE credits

Pharmacists: 1.7 contact hours (0.17 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiretroviral agents
Describe new insights into the management of adverse effects of antiretroviral therapy
Identify the new classes of antiretroviral agents that have been recently approved or are in advanced clinical trials
Discuss the importance of viral tropism in the management of HIV-infected patients

Topics covered include:

ARTEMIS: First-Line Darunavir/Ritonavir vs Lopinavir/Ritonavir
INTERSTART: Use of Interleukin-2 to Defer HAART Initiation
Study 903E: Switch From Stavudine to Tenofovir
BLQ Study: Darunavir/Ritonavir Plus Enfuvirtide in Treatment-Experienced Patients
DUET-1 and -2: Pooled Results of Etravirine vs Placebo, Both in Combination With a Darunavir/Ritonavir-Containing Regimen
TITAN: Analysis of the Development of Resistance
CPCRA Study: Predictors of Disease Progression Based on Viral Tropism
MOTIVATE 1: Final 48-Week Results With Maraviroc in Treatment-Experienced Patients
MOTIVATE 1 and 2: Analysis of the Cause of Treatment Failure
Enhancement of the Phenotypic Coreceptor Tropism Assay
Trial P04100: Follow-up of Treatment-Experienced Patients on Long-term Vicriviroc
Randomized Trial of the CCR5 Inhibitor PRO 140
48-Week Data From Phase II Raltegravir Study in Treatment-Experienced Patients
24-Week Data From Phase II Elvitegravir/Ritonavir Study in Treatment-Experienced Patients
ACTG 5102: Changes in Lipid and Proinflammatory Parameters Following Treatment Interruption
Incidence and Risk Factors for Non-AIDS–Related Events
STACCATO: Hepatitis B Outcomes Related to Use of Tenofovir/Emtricitabine and Treatment Interruption in HIV/HBV-Coinfected Individuals

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.